Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein

FASEB Journal

Volumn 21, Issue 12, 2007, Pages 3075-3082

  Marsche, Gunther ^a   Weigle, Bernd ^b   Sattler, Wolfgang ^a   Malle, Ernst ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Eucodis GmbH   (Austria)

Author keywords

Foam cells; Inflammation; Myeloperoxidase; Oxidized LDL

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CD36 ANTIGEN; HYDROGEN PEROXIDE; HYPOCHLOROUS ACID; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; RAGE PROTEIN; SCAVENGER RECEPTOR; UNCLASSIFIED DRUG; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR; OXIDIZING AGENT; PEPTIDE FRAGMENT; SCARB1 PROTEIN, MOUSE; SCAVENGER RECEPTOR B;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BINDING AFFINITY; CELL INFILTRATION; CHO CELL; CONTROLLED STUDY; FOAM CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION; ANIMAL; CELL LINE; CRICETULUS; CYTOLOGY; GENETICS; HAMSTER; MACROPHAGE; METABOLISM; MOUSE; PATHOLOGY; PROTEIN BINDING;

CRICETULUS GRISEUS;

ANIMALS; ATHEROSCLEROSIS; CELL LINE; CRICETINAE; CRICETULUS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPOCHLOROUS ACID; LIPOPROTEINS, LDL; MACROPHAGES; MICE; OXIDANTS; PEPTIDE FRAGMENTS; PROTEIN BINDING; RECEPTORS, IMMUNOLOGIC; SCAVENGER RECEPTORS, CLASS B;

EID: 35248813974     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.07-8316com     Document Type: Article

References (47)

1. Schmidt, A. M., Yan, S. D., Yan, S. F., and Stern, D. M. (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 108, 949-955
2. Yan, S. F., Ramasamy, R., Naka, Y., and Schmidt, A. M. (2003) Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ. Res. 93, 1159-1169
3. Bierhaus, A., Humpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, D. M., and Nawroth, P. P. (2005) Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 83, 876-886
4. Ramasamy, R., Yan, S. F., and Schmidt, A. M. (2005) The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond. Trends Cardiovasc. Med. 15, 237-243
5. Yamamoto, Y., Kato, I., Doi, T., Yonekura, H., Ohashi, S., Takeuchi, M., Watanabe, T., Yamagishi, S., Sakurai, S., Takasawa, S., et al. (2001) Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J. Clin. Invest. 108, 261-268
6. Bucciarelli, L. G., Wendt, T., Qu, W., Lu, Y., Lalla, E., Rong, L. L., Goova, M. T., Moser, B., Kislinger, T., Lee, D. C., et al. (2002) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106, 2827-2835
7. Cipollone, F., Iezzi, A., Fazia, M., Zucchelli, M., Pini, B., Cuccurullo, C., De Cesare, D., De Blasis, G., Muraro, R., Bei, R., et al. (2003) The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108, 1070-1077
8. Naka, Y., Bucciarelli, L. G., Wendt, T., Lee, L. K., Rong, L. L., Ramasamy, R., Yan, S. F., and Schmidt, A. M. (2004) RAGE axis: animal models and novel insights into the vascular complications of diabetes. Arterioscler. Thromb. Vasc. Biol. 24, 1342-1349
9. Goova, M. T., Li, J., Kislinger, T., Qu, W., Lu, Y., Bucciarelli, L. G., Nowygrod, S., Wolf, B. M., Caliste, X., Yan, S. F., et al. (2001) Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am. J. Pathol. 159, 513-525
10. Wendt, T. M., Tanji, N., Guo, J., Kislinger, T. R., Qu, W., Lu, Y., Bucciarelli, L. G., Rong, L. L., Moser, B., Markowitz, G. S., et al. (2003) RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 162, 1123-1137
11. Kislinger, T., Tanji, N., Wendt, T., Qu, W., Lu, Y., Ferran, L. J., Jr., Taguchi, A., Olson, K., Bucciarelli, L., Goova, M., et al. (2001) Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 21, 905-910
12. Park, L., Raman, K.G., Lee, K.J., Lu, Y., Ferran, L. J., Jr., Chow. W.S., Stern. D., and Schmidt, A. M. (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4, 1025-1031
13. Marsche, G., Semlitsch, M., Hammer, A., Frank, S., Weigle, B., Demling, N., Schmidt, K., Windischhofer, W., Waeg, G., Sattler, W., and Malle, E. (2007) Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway. FASEB J. 21, 1145-1152
14. Cuccurullo, C., Iezzi, A., Fazia, M. L., De Cesare, D., Di Francesco, A., Muraro, R., Bei, R., Ucchino, S., Spigonardo, F., Chiarelli, F., et al. (2006) Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 26, 2716-2723
15. Klebanoff, S. J. (2005) Myeloperoxidase: friend and foe. J. Leukoc. Biol. 77, 598-625
16. Tiruppathi, C., Naqvi, T., Wu, Y., Vogel, S. M., Minshall, R. D., and Malik, A. B. (2004) Albumin mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 101, 7699-7704
17. Carr, A. C., Myzak, M. C., Stocker, R., McCall, M. R., and Frei, B. (2000) Myeloperoxidase binds to low-density lipoprotein: potential implications for atherosclerosis. FEBS Lett. 487, 176-180
18. Hazell, L. J., Arnold, L., Flowers, D., Waeg, G., Malle, E., and Stocker, R. (1996) Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J. Clin. Invest. 97, 1535-1544
19. Zheng, L., Nukuna, B., Brennan, M. L., Sun, M., Goormastic, M., Settle, M., Schmitt, D., Fu, X., Thomson, L., Fox, P. L., et al. (2004) Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114, 529-541
20. Hazell, L. J., and Stocker, R. (1993) Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages. Biochem. J. 290, 165-172
21. Marsche, G., Zimmermann, R., Horiuchi, S., Tandon, N. N., Sattler, W., and Malle, E. (2003) Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modified low density lipoprotein. J. Biol. Chem. 278, 47562-47570
22. Malle, E., Marsche, G., Arnhold, J., and Davies, M. R. (2006) Modification of low-density lipoprotein by myeloperoxidasederived oxidants and reagent hypochlorous acid. Biochim. Biophys. Acta 1761, 392-415
23. Malle, E., Hazell, L., Stocker, R., Sattler, W., Esterbauer, H., and Waeg, G. (1995) Immunologic detection and measurement of hypochlorite-modified LDL with specific monoclonal antibodies. Arterioscler. Thromb. Vasc. Biol. 15, 982-989
24. Takata, K., Horiuchi, S., Araki, N., Shiga, M., Saitoh, M., and Morino, Y. (1988) Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. J. Biol. Chem. 263, 14819-14825
25. Watson, A. D., Leitinger, N., Navab, M., Faull, K. F., Horkko, S., Witztum, J. L., Palinski, W., Schwenke, D., Salomon, R. G., Sha, W., et al. (1997) Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272, 13597-13607
26. Hsieh, H. L., Schafer, B. W., Weigle, B., and Heizmann, C. W. (2004) S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells. Biochem. Biophys. Res. Commun. 316, 949-959
27. Artl, A., Marsche, G., Lestavel, S., Sattler, W., and Malle, E. (2000) Role of serum amyloid A during metabolism of acutephase HDL by macrophages. Arterioscler. Thromb. Vasc. Biol. 20, 763-772
28. Opper, C., Schüssler, G., Sattler, W., and Malle, E. (1998) Effects of hypochlorite-modified low density lipoproteins and high density lipoproteins on platelet function. Platelets 9, 339-341
29. Lander, H. M., Tauras, J. M., Ogiste, J. S., Hori, O., Moss, R. A., and Schmidt, A. M. (1997) Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 272, 17810-17814
30. Kunjathoor, V. V., Febbraio, M., Podrez, E. A., Moore, K. J., Andersson, L., Koehn, S., Rhee, J. S., Silverstein, R., Hoff, H. F., and Freeman, M. W. (2002) Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 277, 49982-49988
31. Hartwich, J., Dembinska-Kiec, A., Gruca, A., Motyka, M., Partyka, L., Skrzeczynska, J., Bzowska, M., Pryjma, J., Huber, J., Leitinger, N., and Schmitz, G. (2002) Regulation of platelet adhesion by oxidized lipoproteins and oxidized phospholipids. Platelets 13, 141-151
32. Krieger, M. (2001) Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J. Clin. Invest. 108, 793-797
33. Hirano, K., Yamashita, S., Nakagawa, Y., Ohya, T., Matsuura, F., Tsukamoto, K., Okamoto, Y., Matsuyama, A., Matsumoto, K., Miyagawa, J., and Matsuzawa, Y. (1999) Expression of human scavenger receptor class B type I in cultured human monocytederived macrophages and atherosclerotic lesions. Circ. Res. 85, 108-116
34. Geroldi, D., Falcone, C., and Emanuele, E. (2006) Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr. Med. Chem. 13, 1971-1978
35. 2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur. J. Biochem. 267, 4495-4503
36. Malle, E., Buch, T., and Grone, H. J. (2003) Myeloperoxidase in kidney disease. Kidney. Int. 64, 1956-1967
37. Hasegawa, T., Malle, E., Farhood, A., and Jaeschke, H. (2005) Generation of hypochlorite-modified proteins by neutrophils during ischemia-reperfusion injury in rat liver: attenuation by ischemic preconditioning. Am. J. Physiol. 289, G760-G767
38. Capeillere-Blandin, C., Gausson, V., Descamps-Latscha, B., and Witko-Sarsat, V. (2004) Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochim. Biophys. Acta 1689, 91-102
39. Liu, S. X., Hou, F. F., Guo, Z. J., Nagai, R., Zhang, W. R., Liu, Z. Q., Zhou, Z. M., Zhou, M., Xie, D., Wang, G. B., and Zhang, X. (2006) Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler. Thromb. Vasc. Biol. 26, 1156-1162
40. Hazen, S. L., and Heinecke, J. W. (1997) 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest. 99, 2075-2081
41. Febbraio, M., Hajjar, D. P., and Silverstein, R. L. (2001) CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest. 108, 785-791
42. Podrez, E. A., Febbraio, M., Sheibani, N., Schmitt, D., Silverstein, R. L., Hajjar, D. P., Cohen, P. A., Frazier, W. A., Hoff, H. F., and Hazen, S. L. (2000) Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J. Clin. Invest. 105, 1095-1108
43. Podrez, E. A., Poliakov, E., Shen, Z., Zhang, R., Deng, Y., Sun, M., Finton, P. J., Shan, L., Gugiu, B., Fox, P. L., et al. (2002) Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J. Biol. Chem. 277, 38503-38516
44. Han, J., Hajjar, D. P., Tauras, J. M., and Nicholson, A. C. (1999) Cellular cholesterol regulates expression of the macrophage type B scavenger receptor, CD36. J. Lipid Res. 40, 830-838
45. Huh, H. Y., Pearce, S. F., Yesner, L. M., Schindler, J. L., and Silverstein, R. L. (1996) Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. Blood 87, 2020-2028
46. Rahaman, S. O., Lennon, D. J., Febbraio, M., Podrez, E. A., Hazen, S. L., and Silverstein, R. L. (2006) A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell. Metab. 4, 211-221
47. Yonekura, H., Yamamoto, Y., Sakurai, S., Petrova, R. G., Abedin, M. J., Li, H., Yasui, K., Takeuchi, M., Makita, Z., Takasawa, S., et al. (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 370, 1097-1109